Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative

Area of Science:

• Pharmacology
• Computational Biology
• Cardiovascular Science

Background:

• Established cardiotoxicity guidelines (ICH 2005) focus on hERG channel blockade and QT/QTc prolongation for Torsade de Pointes (TdP) risk.
• Current biomarkers (QTc prolongation) lack specificity for TdP risk due to the influence of multiple ion channels on cardiac action potentials.
• Limitations in existing models necessitate a more comprehensive approach to cardiac safety assessment.

Purpose of the Study:

• To introduce the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative and its objective to develop a standardized in silico model.
• To quantitatively evaluate cardiac response and assess TdP risk using a novel computational metric.
• To provide clinical pharmacologists with an understanding of the CiPA in silico modeling process.

Main Methods:

• Development of a standardized and reliable in silico model of a human ventricular cell.
• Implementation involves hERG channel fitting, Hill fitting, and cardiac action potential simulations.
• Quantitative evaluation of cellular cardiac electrophysiologic activity to predict TdP risk.

Main Results:

• A standardized in silico model and a quantitative metric for TdP risk assessment have been developed.
• The model enables a more accurate evaluation of cardiac electrophysiologic activity compared to previous methods.
• CiPA studies demonstrate the potential for improved prediction of drug-induced cardiac events.

Conclusions:

• The CiPA initiative offers a significant advancement in assessing drug-induced cardiotoxicity and TdP risk.
• The developed in silico model provides a robust tool for quantitative cardiac safety evaluation.
• This approach enhances the understanding and prediction of proarrhythmic potential in drug development.